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A B S T R A C T
In the prospective study the susceptibility of 41 Escherichia coli strains and 55 Pseudomonas aeruginosa strains to
gentamicin, netilmicin and amikacin was tested at a 2-year interval (period I April 1998 to March 1999, and period II
April to July 2001). Genotyping was performed by pulsed-field gel electrophoresis, and a clone based on 80% or 90% sim-
ilarity was determined for each of the study bacteria. In 24 (32.0%) clones, strains showed no variation over 2-year inter-
val, supporting the hypothesis on a priori susceptible strains. Transformation from susceptibility in period I to resistance
in period II was demonstrated in 5 (6.7%) clones, a pattern consistent with the concept of bacterial development of resis-
tance under the influence of antibiotics. However, there were 10 (13.3%) clones whose strains exhibited an inverse pattern.
Accordingly, two-way transformation of susceptibility took place during the study period. The utilization of the study
aminoglycosides had no major impact on the variation of microbial susceptibility. Changes in microbial susceptibility
were found to follow some regular patterns, which were not influenced by the study aminoglycosides. Two phenomena
were observed: (i) there were stable clones that did not develop resistance in spite of selective antibiotic challenge; and (ii)
changes of susceptibility in isolated bacteria from both inpatient and outpatient strains of the same clone were two-way
and reversible.
Key words: aminoglycosides, antimicrobial resistance, change of susceptibility, clone, pulsed-field gel electrophore-
sis, Escherichia coli, Pseudomonas aeruginosa
Introduction
Microbial resistance to aminoglycosides (or antibiot-
ics in general) poses an increasing problem all over the
world1–3, especially in seriously ill patients4–6. Literature
reports on the strategies used to prevent the spread of
microbial resistance to various antibiotics (a multidisci-
plinary issue), including the three aminoglycosides tes-
ted in the present study (gentamicin, amikacin and netil-
micin), have been almost exclusively focused on microbial
resistance in inpatient settings7. These problems are pro-
nounced in hospitals, as they involve hospitalized pa-
tients characterized by reduced defense responsiveness
due to the underlying disease and administration of one
or more antibiotics8–17.
How do antibiotics promote resistance? The proce-
dure of selection may only seem to be easy. Every time an
antibiotic exerts its effect, the sensitive bacteria will
gradually die. Bacteria as target organisms may survive
the action of antibiotics if possessing any kind of resis-
tance before their exposure to antibiotics or if they have
acquired it later (by mutation or gene exchange). These
bacteria should continue to multiply despite the presence
of antibiotics, leaving resistant clones behind. Is it really
going to happen? What are the present relations between
the resistant and susceptible clones (strains) in the mi-
crobial population?
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Every time an antibiotic is administered, in addition
to its effect on the target pathogenic microorganism it
definitely has an effect on the normal bacterial flora of
the body. The normal bacterial flora will have the very
same response to the antibiotic and will develop resis-
tance in the very same way as the target pathogenic mi-
croorganism. The increase in non-pathogenic but resis-
tant bacteria is accompanied by the growth of the resis-
tance reservoir in the microbial population, thus increas-
ing the likelihood and rate of acquiring or transmitting
resistance genes to various types of pathogenic and non-
-pathogenic bacteria. Besides, are we sure that antibiot-
ics have an effect on resistance increase? Nowadays,
biocides are often administered, posing the question of
the extent of their effect on the occurrence of resi-
stance18. In nature, there are residues of antibiotics that,
in addition to other organic and inorganic compounds,
definitely have an effect on the bacteria and their resis-
tance. Are we in for the use of normal flora as an impor-
tant factor in the combat against resistance19,20?
In veterinary medicine and agriculture, antibiotics
are used not only for therapeutic purpose but also for
prophylaxis and food improvement (as growth promot-
ers). There is no doubt that antibiotics exist in our envi-
ronment, wherefrom they may again influence the devel-
opment of resistance21. Human medicine does not have
continued antibiotic prevention, as is a common practice
in veterinary medicine and agriculture. Yet, aren’t hu-
man beings under constant influence of antibiotics, as
certain quantities of various types of antibiotics are ap-
proved, e.g., in milk and meat? Physicians aiming only at
preserving and improving human health cannot accept
the fact that the occurrence of resistance is due to the use
of antibiotics as growth promoters in food animals, me-
rely to increase the profit of food industry. On the other
hand, one cannot conceive the consequences that would
be entailed by placing a ban, substantially reducing or
stipulating strict conditions for the administration of an-
tibiotics to food animals, as it would cause enormous fi-
nancial losses22–24. In Europe, the use of antibiotics for
alimentary purposes has been legally regulated since
1987. It has been clearly stated that antibiotics cannot
and may not be a substitute for poor conditions and hy-
giene of animal keeping. Yet, no such regulations have
been developed on the respective treatments and pro-
phylaxis25.
Based on monitoring and comparison of total antibi-
otic utilization with changes in antimicrobial resistance
in different countries, it is quite clear that a reduction or
increase in the utilization of antibiotics may but need not
always be associated with a resistance decrease or in-
crease. This is so because of the very complex relation-
ship between the microorganisms and the use of antibiot-
ics, not only in the field of health care but also in the
fields of veterinary medicine and agriculture26.
In the combat against the development of hospital re-
sistance to antibiotics in general, including aminogly-
cosides, there are very similar strategies based on some
common elements: (i) understanding the reasons and
routes of occurrence and spread of antimicrobial resis-
tance; (ii) reducing the »empiric« antibiotic utilization by
accurate and rapid identification of the causative agents;
(iii) withdrawing and reintroducing an antibiotic in ther-
apeutic protocol at certain intervals (cycling), thus to ac-
tively influence the development of resistance; and (iv)
administration of several antibiotics in individual pa-
tient therapy (rotation)27.
Considering total resistance of microorganisms men-
tioned in the literature from this (limited) aspect, any
evaluation of the antibiotic – bacterium relationship ap-
pears to be based on inpatient resistance. To our knowl-
edge, there are no reports addressing the issues of micro-
bial susceptibility or resistance through treatment of a
part of the total microbial population as a temporally
changeable (dynamic) entity in which all changes and in-
fluences happen that determine the bacterium as a living
organism the attitude of which is in accordance with only
some of the regularities observed. Therefore, the aim of
this study was to observe the effect of aminoglycosides on
the dynamics of change in microbial susceptibility at a
two-year interval in inpatient and outpatient samples.
Material and Methods
Materials
In order to demonstrate the effect of study amino-
glycosides (gentamicin, amikacin and netilmicin) on the
development of resistance in E. coli and P. aeruginosa
strains, samples were collected at a two-year interval.
Samples of blood, urine, throat swabs and surgical wounds
were obtained from patients hospitalized at Osijek Uni-
versity Hospital (OUH) (experimental group) and pa-
tients visiting primary health care (PHC) offices for
low-grade infections (control group). First sampling was
performed from April 1998 to March 1999 (period I), and
second sampling from April to July 2001 (period II). PHC
samples were obtained from patients that had not been
hospitalized for the past five years. These samples served
as a control group, since the study aminoglycosides are
not used at PHC at all. Samples were stored in liquid ni-
trogen and revitalized immediately before submitting to
pulsed-field electrophoresis. A questionnaire containing
demographic data, date of sampling, OUH department or
PHC office, type of sample, and results of susceptibility
to study aminoglycosides was filled out for each sample.
Methods
The isolation, identification and determination of an-
tibiotic susceptibility of bacteria were performed by the
method of disk diffusion28. Bacterial susceptibility to
study aminoglycosides (susceptible 3, resistant 2 or 0)
was semi-qualitatively determined by disk diffusion in
agar using standard methodology29–30. Strains were kept
in liquid nitrogen until genotyping. Quantitative deter-
mination of susceptibility is based on dilution in bouil-
lon. Strain genotyping was performed by pulsed-field gel
electrophoresis (PFGE) on a CHEF III (BioRad) device31.
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Between-strain comparison was done by use of GelCom-
par II software (Applied Maths, Sint-Martens-Latem,
Belgium).
Definitions
A clone represented 80% affinity or similarity of bac-
terial strains for each of the aminoglycosides tested (90%
due to P. aeruginosa variability), based on genotyping,
i.e. it represented the similarity between DNA fragments
upon restriction. Clones were not produced on the basis
of phylogenic similarity; the GelCompar II software was
used to determine the strains belonging to a particular
clone and the level (%) of similarity. The clones exerting
the very same dynamics of susceptibility over two years
yielded four pattern types: (a) stable clones detected in
both periods, their susceptibility or resistance being un-
changed, stable clones; (b) clones detected in only one pe-
riod, their change of susceptibility could not be moni-
tored; (c) clones showing transformation from resistance
in period I to susceptibility in period II; and (d) clones
showing transformation from susceptibility in period I to
resistance in period II.
Statistical analysis
Statistical analyses were performed with the Statisti-
cal Package for the Social Sciences, version 15.0 (SPSS
Inc., Chicago, IL, USA). c2 test (df=1) was used for the
analysis of differences between strains of each pattern.
The level of significance was set at P<0.05. E. coli and P.
aeruginosa resist types (gentamicin-amikacin-netilmicin,
GAN) are presented as absolute and relative frequencies.
A statistical model of 2x2 contingency tables was used on
data processing32.
Results
A total of 320 (158 inpatient and 162 outpatient) sam-
ples were collected, of which 221 E. coli strains (89 inpa-
tient and 132 outpatient) and 99 P. aeruginosa strains
(69 inpatient and 30 outpatient) were isolated during the
two study periods. Of these, 41 E. coli strains and 55 P.
aeruginosa strains were retrieved by revitalization.
Throughout the study periods, the highest proportion
of E. coli resist types susceptible to all three study
aminoglycosides (gentamicin, amikacin and netilmicin,
GAN-1, n=28) and a low proportion of resistant resist
types were detected (GAN-5, n=4) (Table 1). Other resist
types as transient forms between GAN-1 and GAN-5
were rarely recorded. Most frequently GAN-1 resist type
was isolated from both inpatient and outpatient samples.
Of the aminoglycosides tested, E. coli showed highest
rate of resistance to gentamicin (31.7%), followed by
netilmicin (22%) and amikacin (12.2%).
P. aeruginosa showed quite a different distribution of
resist types, predominated by GAN-5 resist type (n=19),
followed by GAN-1 resist type (n=18) (Table 2). It should
be noted that GAN-3 resist type resistant to gentamicin
and netilmicin (n=17) was ranked between GAN-1 and
GAN-2. Of the three aminoglycosides tested, P. aeru-
ginosa showed highest rate of resistance to gentamicin
(67.3%), followed by netilmicin (65.5%) and amikacin
(34.5%).
Utilization of aminoglycosides
Between 1997 and 2001, the utilization of amikacin
was on a constant decline, however, a significant decrease
was only recorded between 1998 and 1999 (c2 = 322.115,
P<0.005). The utilization of gentamicin increased, with
an abrupt one-year rise in 1999. The utilization of gen-
tamicin showed considerable oscillation, i.e. an increase
in 1998–1999 (c2=5359.170, P<0.005), a decrease in
1999–2000 (c2=1716.843, P<0.005), to rise again in
2000–2001 (c2=3350.033, P<0.005). The utilization of
netilmicin during the five-year study period showed a
substantial rise in the first two years, to fall abruptly in
1999 (c2=1840,211, P<0.005), and rise in 2000
(c2=7755,331, P<0.005) (Figure 1).
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TABLE 1
NUMBER OF ESCHERICHIA COLI RESIST TYPES STRAINS
ACCORDING TO STUDY PERIODS (N=41)
GAN-1 GAN-2 GAN-3 GAN-4 GAN-5
+++ –++ –+– ––+ –––
Period I II I II I II I II I II
Inpatient 3 13 0 2 2 1 0 0 2 1
Outpatient 8 4 1 0 0 2 0 1 1 0
Total 28 3 5 1 4
*GAN-1... GAN-5 – gentamicin-amikacin-netilmicin resist types
*»–« – resistant to aminoglycosides, »+« susceptible to amino-
glycosides
TABLE 2
NUMBER OF PSEUDOMONAS AERUGINOSA RESIST TYPES
STRAINS ACCORDING TO STUDY PERIODS (N=55)
GAN-1 GAN-2 GAN-3 GAN-5
+++ –++ –+– –––
Period I II I II I II I II
Inpatient 10 4 1 0 10 0 5 8
Outpatient 2 2 0 0 6 1 4 2
Total 18 1 17 19
*GAN-1... GAN-5 – gentamicin-amikacin-netilmicin resist types





















Fig. 1. Aminoglycoside utilization at Osijek University Hospital
1997–2001.
PFGE
Genotyping was performed in 41 E. coli strains and 55
P. aeruginosa strains that were successfully revitalized
upon removal from liquid nitrogen. All 41 E. coli strains
were classified into 20 clones at a similarity level of 80%.
Of these, 12/20 (60%) clones had at least two or more
strains, 8/12 (66.7%) clones contained strains from both
inpatient and outpatient samples. 8/20 (40%) clones had
only one strain (Figure 2).
P. aeruginosa strains were arranged in the form of 18
clones at a similarity level of 90% because they would
form nearly one clone at the 80% level of similarity; 13/18
(72.2%) clones contained at least 2 strains, and 5/18
(27.8%) clones only one strain; 4/13 (30.8%) clones con-
tained strains from both inpatient and outpatient sam-
ples (Figure 3).
The clones containing one strain were excluded from
further analysis. The change of susceptibility in strains
of a clone between the two study periods was assessed for
each of the study bacteria and antibiotics. The clones
showing the same pattern of susceptibility change irre-
spective of the bacterium and antibiotic involved formed
the same pattern. Considering the change of susceptibil-
ity of each clone to each of the study antibiotics over the
two-year period, each clone (Figure 3) additionally for-
med three new clones to each of the three antibiotics.
Thus, there were 75 clones in total, which yielded four
different patterns (Table 3). In pattern A (24/75, 32%),
the strains found in 24/24 clones (100%) exhibited per-
manent (unchanged) susceptibility to the study amino-
glycosides in both study periods, irrespective of the inpa-
tient or outpatient sample origin. None of the pattern A
clones contained strains resistant to study aminogly-
cosides in both study periods.
The predominant pattern B (36/75, 48%) contained
various clones with strains susceptible and/or resistant
to study aminoglycosides, however, only detected in one
of the study periods, thus precluding determination of
their pattern of susceptibility dynamics.
In pattern C, transformation from resistance to sus-
ceptibility (10/75, 13.3%) between periods I and II was
recorded in 9 clones (12.2%; c2=14.845; p<0.005), whe-
reas pattern D (5/75, 6.7%) showed inverse transforma-
tion from susceptibility to resistance in 4 clones (5.4%).
Comparison of the parameters of antibiotic suscepti-
bility between inpatient and outpatient strains pointed
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TABLE 3
NUMBER OF E. COLI AND P. AERUGINOSA PATTERNS ACCORDING TO SUSCEPTIBILITY TO STUDY AMINOGLICOSIDES
Sampling period
1998/1999 –2001
































 changing toward resistance
* »3« – susceptibility, »0« – resistance
Fig. 2. PFGE clones of E. coli at 80% level of strain similarity.
Dendrogram generated by GelCompar II software showing the
PFGE clonal groups identified among E. coli isolates from inpa-
tient and outpatient. Vertical bold line indicate similarity index.
Horizontal bold lines distinguish different clones. Odjel 1 – 4 –
Osijek University Hospital departments (inpatient), Odjel 5 –
Primary Health Care (outpatient), E1–E20 – clones of E. coli.
to the following conclusions applying to all strains of the
study bacteria: 1) the coverage of susceptible strains in
period II ranged from 44% to 68%; 2) support was sli-
ghtly higher in inpatient than in outpatient strains; 3)
the strength of transformation to resistant strains was
higher in inpatient strains; and 4) the lift by approxi-
mately 1 indicated a weak intensity of transformation of
susceptible strains in period I to resistant strains in pe-
riod II (Table 4).
Discussion
Although employing microbiological methods, the
present study was primarily focused on the bacterium –
aminoglycosides inter-relationship from the epidemio-
logical rather than microbiological point of view. During
the study period, the utilization of gentamicin and ne-
tilmicin was on a considerable increase, while the utiliza-
tion of amikacin showed a substantial decline due to fina-
ncial reasons. However, these changes in aminoglyco-
sides utilization were not accompanied by respective
changes in the susceptibility of the tested E. coli and P.
aeruginosa strains to gentamicin, amikacin and netil-
micin. Changes in microbial susceptibility were found to
follow some regular patterns, which were not influenced
by the study aminoglycosides. Two phenomena were ob-
served: (i) there were stable clones that did not develop
resistance in spite of selective antibiotic challenge; and
(ii) changes of susceptibility in isolated bacteria from
both inpatient and outpatient strains of the same clone
were two-way and reversible.
Considering the study aminoglycosides, 2/3 E. coli
strains were susceptible to gentamicin, which was a sub-
stantially lower rate as compared with other amino-
glycosides, although the utilization of gentamicin was
several times lower than the utilization of netilmicin in
particular years of the study period. Accordingly, it ap-
pears that the utilization of study aminoglycosides alone
had no major role in the development of E. coli resis-
tance, and probably gained in importance only in con-
junction with other factors.
Despite the decline recorded in the utilization of ami-
kacin over several years, there were no substantial chan-
ges in the susceptibility pattern of P. aeruginosa. The
finding of 36 clones belonging to pattern B (Table 3) may
suggest that a considerably longer time than two years is
needed for the reversible, two-way changes of P. aeru-
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TABLE 4
TABLE OF CONTIGENCY ON STUDY BACTERIA AND AMINOGLYCOSIDES
Sampling site Coverage (%) Support (%) Strength (%) Lift
Gentamici
Inpatient 44 20 45 0.99
Outpatient 47 24 50 1.00
Average 45 21 47 0.99
Amikacin
Inpatient 65 28 65 1,05
Outpatient 68 29 68 1,06
Average 66 29 66 1,05
Netilmicin
Inpatient 46 19 42 0,99
Outpatient 50 24 47 1,00
Average 47 21 44 0,99
Fig. 3. PFGE clones of P. aeruginosa at 90% level of strain simi-
larity. Dendrogram generated by GelCompar II software show-
ing the PFGE clonal groups identified among P. aeruginosa iso-
lates from inpatient and outpatient. Vertical bold line indicate
similarity index. Horizontal bold lines distinguish different clo-
nes. Odjel 1–4 – Osijek University Hospital departments (inpa-
tient), Odjel 5 – Primary Health Care (outpatient), P1–P18 – clo-
nes of P. aeruginosa.
ginosa (unlike E. coli) susceptibility to be observed. Con-
sidering P. aeruginosa susceptibility to gentamicin and
netilmicin, resistant strains were found to prevail, which
was consistent with the utilization of these antibiotics.
Four patterns could be formed of 75 clones of the
study bacteria and aminoglycosides. Pattern A consisted
of clones that did not change their susceptibility over the
two-year period (n=24, 32.4%). These data speak for the
fact that there are strains that do not change their sus-
ceptibility at all, irrespective of the selective amino-
glycosides challenge. The most common pattern B con-
tained various clones (36, 48%) with strains that were
either susceptible or resistant to the study aminogly-
cosides, but were only detected in one of the study peri-
ods. Therefore, the pattern of susceptibility modification
could not be determined in these clones. The clones of
this particular pattern would require the number of sam-
pling to increase, or reduce (for E. coli) or the interval be-
tween sampling procedures to increase (P. aeruginosa).
The clones of pattern D (n=5, 6.7%) developed or oth-
erwise acquired resistance genes under the influence of
antibiotics, which was consistent with the current state-
-of-the-art on the issue.
The clones of pattern C (n=10, 13.3%) showed strain
transformation from resistance in period I towards sus-
ceptibility to aminoglycosides in period II, indicating the
occurrence of an inverse change of susceptibility, to our
knowledge not described to date. Thus, sharply opposed,
inverse processes of changing resistance to aminogly-
cosides took place in the bacterial population over a cer-
tain period of time irrespective of the utilization of the
study aminoglycosides. So, the hypothesis on a minor
proportion of resistant clones found in period I and ex-
pected to substantially increase in period II due to the ef-
fect of aminoglycosides was only in part confirmed by
these observations. In other words, the behavior of pat-
tern C clones shed some new light upon the bacterium –
antibiotic relations, where a resistant bacterium of a
clone need not maintain antibiotic resistance perma-
nently or over a prolonged period of time, therefore the
resistant strain of the clone need not turn predominant
with time. This will only be possible to demonstrate in
additional studies that should include at least three
samplings at three different time intervals. The impact
of aminoglycosides on the development of resistance of
the study bacteria was statistically non-significant, as
also confirmed by the low intensity of the lift of suscepti-
ble strains in period I to resistant strains in period II,
which was 1. (Table 4)
Resistant strains of a clone were not only detected in
inpatient samples, characterized by seriously ill patients,
large-scale use of antibiotics, and conditions favoring the
development of resistant strains, but also in outpatient
samples collected from individuals visiting PHC offices.
This finding showed that resistant strains of the study
bacteria were as widely spread in inpatient and outpa-
tient microbiological settings. Appropriate choice and
monitoring of a consistent strategy of aminoglycosides
utilization (e.g., antibiotic rotation, cycling, etc.) appear
to play a more important role in the management of pa-
tients with resistant causative agents (nosocomial infec-
tion) than in the control of the spread of resistance in the
study bacteria (or microbial resistance in general). Hos-
pital system is not a closed system; it may only be easier
or simpler to identify microbial resistance due to the dis-
ease severity and patient treatment. That is why the is-
sue of microbial resistance is currently perceived and in-
terpreted exclusively from the hospital view, thus obviating
the fact that the hospital microbiological setting is just a
segment of the overall integral microbiological system in
which resistant strains are probably impossible to con-
fine within the site of their generation. In healthy or less
severely ill carriers of resistant clones from the outpa-
tient population, their health is generally normal or only
slightly impaired, thus the problem of microbial resis-
tance being by far less pronounced as compared with the
inpatient population. In the present study, there was no
significant susceptibility difference between inpatient
and outpatient isolates, suggesting a high and rapid
strain circulation between these two settings. If it were
exclusively the antibiotics that determine the develop-
ment and spread of microbial resistance (taking decades
of their administration into account), the question arises
why resistant strains have not yet spread so as to pre-
dominate the microbial population at large, after decades
of the use of antibiotics?
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UTJECAJ UPORABE AMINOGLIKOZIDA NA NASTANAK I [IRENJE OTPORNIH BAKTERIJA
S A @ E T A K
U razmaku od 2 godine (1998/1999 i 2001) ispitana je osjetljivost 41 soja Escerichie coli (E. coli), 55 sojeva Pseudo-
monas aeruginosa (P. aeruginosa) na gentamicin, netilmicin i amikacin. Za genotipizaciju kori{tena je pulsfieldgele-
ktroforeza (PFGE). Klonovi su za svaku bakteriju odre|eni na temelju sli~nosti od 80%, odnosno 90%. Cilj je ispitivanja
promatrati djelovanje aminoglikozida na dinamiku promjena osjetljivosti sojeva nekog klona u razmaku od 2 godine u
navedenim bakterijama i iz bolni~kih i iz izvanbolni~kih uzoraka. Najve}i je broj klonova ~iji su sojevi prona|eni samo u
jednom ispitanom razdoblju (36, 48%) te se za njih nije mogla odrediti promjena osjetljivosti izme|u dva razdoblja od 2
godine. U 24 klona (32%) sojevi u razmaku od 2 godine nisu mijenjali osjetljivost. Ovi podaci govore u prilog hipotezi da
a priori postoje osjetljivi i otporni sojevi. U 5 (6,7%) klonova dokazana je promjena od osjetljivosti sojeva u prvom
razdoblju prema otpornosti u drugom razdoblju. Ovakvo pona{anje je sukladno shva}anju da bakterije razvijaju otpor-
nost pod djelovanjem antibiotika. Me|utim, dokazano je i postojanje 10 (13,3%) klonova ~iji sojevi pokazuju suprotno:
otporni sojevi iz prvog razdoblja »gube« otpornost i postaju osjetljivi u drugom razdoblju. Dakle, u promatranom su
vremenu promjene osjetljivosti dvosmjerne. 88% klonova sadr`e sojeve i iz bolni~kih i iz izvanbolni~kih uzoraka {to
ukazuje da nema vi{e zatvorenih sredina. Potro{nja ispitanih aminoglikozida ne utje~u na promjenu osjetljivosti.
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